natgillin/translations-raw huggingface dataset:
The effect of co-administration of Genvoya with oral contraceptives containing progestagens other than norgestimate is not known and therefore should be avoided.
Učinek sočasne uporabe zdravila Genvoya s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, ni znan, zato se ji je treba izogniti.
The effect of co-administration of Genvoya with oral contraceptives containing progestagens other than norgestimate is not known and, therefore, should be avoided.
Učinki sočasne uporabe zdravila Genvoya s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, niso znani, zato se ji je treba izogniti.
The effect of cobicistat on atazanavir pharmacokinetics was demonstrated in the pharmacokinetic sub- study (n = 48) of the phase 3 study GS-US-216-0114 in which HIV-1 infected patients received atazanavir 300 mg + cobicistat 150 mg or atazanavir 300 mg + ritonavir 100 mg, both in combination with emtricitabine and tenofovir disoproxil fumarate fixed-dose combination.
Učinek kobicistata na farmakokinetiko atazanavirja je bil dokazan v farmakokinetični podštudiji (n = 48) študije GS-US-216-0114 faze 3, v kateri so bolniki, okuženi z virusom HIV-1, prejemali atazanavir 300 mg + kobicistat 150 mg ali atazanavir 300 mg + ritonavir 100 mg, oba sočasno s fiksno kombinacijo emtricitabina in dizoproksiltenofovirat fumarata.
The effect of cobicistat on serum creatinine and eGFR in patients switching from ritonavir to cobicistat in study GS-US-236-0118 was consistent with the effect in treatment-naïve patients in study GS-US-216-0114.
Učinek kobicistata na raven kreatinina v serumu in eGFR pri bolnikih, ki so v študiji GS-US-236-0118 z ritonavirja prešli na kobicistat, je bil skladen z učinkom pri bolnikih v študiji GS-US-216-0114, ki se predhodno še niso zdravili.
The effect of concomitant administration of Lojuxta with other hepatotoxic medicine is unknown.
Učinek sočasne uporabe zdravila Lojuxta z drugimi hepatotoksičnimi zdravili ni znan.
The effect of conestat alfa on the following target proteases was assessed in vitro: activated C1s, kallikrein, factor XIIa and factor XIa.
In vitro so ugotavljali učinek konestata alfa na naslednje tarčne proteaze: aktivirani C1, kalikrein, faktor XIIa in faktor XIa.
The effect of CsA was also reflected by increases in sirolimus Cmax and tmax.
Učinek CsA se je pokazal tudi v zvečanju Cmax in tmax sirolimusa.
The effect of Cymbalta 60 mg once a day in elderly depressed patients (65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17 score for duloxetine-treated patients compared to placebo.
Pri starejših depresivnih bolnikih ( 65 let) so posebej preučevali učinek zdravila Cymbalta 60 mg enkrat na dan v študiji, ki je pokazala statistično pomembno razliko v zmanjšanju HAMD17 rezultata za bolnike, ki so bili zdravljeni z duloksetinom, v primerjavi s tistimi, ki so prejemali placebo.
The effect of dasatinib on sperm is unknown (see section 5.3).
Vpliv dasatiniba na spermo ni znan (glejte poglavje 5.3).
The effect of dolutegravir on human pregnancy is unknown.
Vpliv dolutegravirja na nosečnost pri ljudeh ni znan.
The effect of doxorubicin hydrochloride on human fertility has not been evaluated (see section 5.3).
Učinka doksirubicinijevega klorida na plodnost pri človeku niso ocenjevali (glejte poglavje 5.3).
The effect of DUAVIVE on the risk of breast cancer is unknown.
Vpliv zdravila DUAVIVE na tveganje za raka dojke ni znan.
The effect of DUAVIVE on the risk of dementia is unknown.
Vpliv zdravila DUAVIVE na tveganje za demenco ni znan.
The effect of DUAVIVE on the risk of stroke is unknown.
Vpliv zdravila DUAVIVE na tveganje za možgansko kap ni znan.
The effect of dulaglutide on blood pressure as assessed by Ambulatory Blood Pressure Monitoring was evaluated in a study of 755 patients with type 2 diabetes.
Učinek dulaglutida na krvni tlak, ocenjen med 24-urnim merjenjem krvnega tlaka, je bil ocenjen v študiji s 755 bolnikih s sladkorno boleznijo tipa 2.
The effect of duloxetine 60 mg once a day in elderly depressed patients (≥65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17 score for duloxetine-treated patients compared to placebo.
Pri starejših depresivnih bolnikih ( 65 let) so posebej preučevali učinek duloksetina 60 mg enkrat na dan v študiji, ki je pokazala statistično pomembno razliko v zmanjšanju HAMD17 rezultata za bolnike, ki so bili zdravljeni z duloksetinom, v primerjavi s tistimi, ki so prejemali placebo.
The effect of Duloxetine Lilly 60 mg once a day in elderly depressed patients (65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17 score for duloxetine-treated patients compared to placebo.
Pri starejših depresivnih bolnikih ( 65 let) so posebej preučevali učinek zdravila Duloxetine Lilly 60 mg enkrat na dan v študiji, ki je pokazala statistično pomembno razliko v zmanjšanju HAMD17 rezultata za bolnike, ki so bili zdravljeni z duloksetinom, v primerjavi s tistimi, ki so prejemali placebo.
The effect of efavirenz on male and female fertility in rats has only been evaluated at doses that achieved systemic drug exposures equivalent to or below those achieved in humans given recommended doses of efavirenz.
Učinek efavirenza na plodnost podganjih samcev in samic je bil ovrednoten le pri odmerkih, pri katerih so bile dosežene enake ali manjše sistemske izpostavljenosti zdravilni učinkovini kot pri ljudeh, ki so jemali priporočene odmerke efavirenza.
The effect of epoetin alfa (300 IU/kg or 100 IU/kg) on the exposure to allogeneic blood transfusion has been evaluated in a placebo-controlled, double-blind clinical trial in non-iron deficient adult patients scheduled for major elective orthopaedic hip or knee surgery.
Učinek epoetina alfa (300 i.e./kg ali 100 i.e./kg) na izpostavljenost alogenski transfuziji krvi so ocenili v s placebom nadzorovnem, dvojno slepem kliničnem preskušanju pri odraslih bolnikih brez pomanjkanja železa, ki imajo načrtovan večji elektivni ortopedski kirurški poseg na kolku ali kolenu.
The effect of epoetin alfa in facilitating autologous blood donation in patients with low haematocrits (≤ 39% and no underlying anaemia due to iron deficiency) scheduled for major orthopaedic surgery was evaluated in a double-blind, placebo-controlled study conducted in 204 patients, and a single- blind placebo controlled study in 55 patients.
Učinek epoetina alfa na lajšanje avtolognega darovanja krvi pri bolnikih z nizkimi hematokriti (≤ 39 % in brez osnovne anemije zaradi pomanjkanja železa), ki imajo načrtovan večji ortopedski kirurški poseg, je bila ocenjena v dvojno slepi, s placebom nadzorovani študiji, ki so jo izvedli pri 204 bolnikih, in v enojno slepi, s placebom nadzorovani študiji s 55 bolniki.
The effect of Fabrazyme treatment on the kidneys may be limited in patients with advanced renal disease.
Pri bolnikih z napredovalo ledvično boleznijo bo morda učinek zdravljenja z zdravilom Fabrazyme na ledvicah omejen.
The effect of food on the bioavailability of cholic acid has not been studied.
Učinka hrane na biološko razpoložljivost holne kisline niso preučili.
The effect of FOSAVANCE (alendronate 70 mg/vitamin D3 2,800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range,
Vpliv zdravila FOSAVANCE (alendronat 70 mg/vitamin D3 2.800 i.e.) na status vitamina D so ugotavljali v 15-tedenski, mednarodni študiji, v katero je bilo vključenih 682 žensk s pomenopavzalno osteoporozo (serumski 25-hidroksivitamin D ob začetku študije: povprečna vrednost 56 nmol/l
The effect of glimepiride is dose- dependent and reproducible.
Učinek glimepirida je odvisen od odmerka in je ponovljiv.
The effect of hepatic impairment on exposure to Lynparza has not been studied.
Vpliv okvare jeter na izpostavljenost zdravilu Lynparza ni raziskan.
The effect of hepatic impairment on exposure to olaparib has not been studied.
Vpliv okvare jeter na izpostavljenost olaparibu ni raziskan.
The effect of hepatic impairment on the absorption of inhaled human insulin has not been studied (see section 4.2).
Učinka okvar jeter na absorpcijo humanega insulina za inhaliranje niso proučevali (glejte poglavje 4.2).
The effect of inhibitors of CYP2C8 (gemfibrozil), inhibitors of UGT1A3 and UGT2B7 (valproic acid, probenecid, and fluconazole), inducers of CYP2C8 (rifampicin, rifapentine), or inducers of UGT1A3, and UGT2B7 (rifampicin) on the exposure to selexipag and its active metabolite has not been studied.
Učinka zaviralcev CYP2C8 (gemfibrozil), zaviralcev UGT1A3 in UGT2B7 (valprojska kislina, probenecid in flukonazol), induktorjev CYP2C8 (rifampicin, rifapentin) ali induktorjev UGT1A3 in UGT2B7 (rifampicin) na izpostavljenost seleksipagu in njegovemu aktivnemu presnovku niso preučili.
The effect of Kinzalkomb may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinek zdravila Kinzalkomb se lahko, zmanjša, če jemljete NSAR (nesteroidne antirevmatike, npr. acetilsalicilno kislino ali ibuprofen).
The effect of Kinzalmono may be reduced when you take NSAIDs (non steroidal anti-inflammatory mediciens, e.g. aspirin or ibuprofen) or corticosteroids.
Učinek zdravila Kinzalmono se lahko zmanjša, če jemljete nesteroidna protivnetna zdravila (na primer aspirin ali ibuprofen) ali kortikosteroide.
The effect of known cytidine deaminase polymorphisms on azacitidine metabolism has not been formally investigated.
Učinka znanih polimorfizmov citidin deaminaze na presnovo azacitidina niso formalno preučevali.
The effect of LDL-C lowering is sustained; the longest duration measured was 112 weeks.
Učinek znižanja LDL-H je dolgotrajen; najdaljše izmerjeno trajanje je bilo 112 tednov.
The effect of Lonsurf on overall survival was similar in patients <65 years and ≥65 years of age.
Učinek zdravila Lonsurf na podaljšanje celokupnega preživetja je bil pri bolnikih < 65 let in bolnikih ≥ 65 let podoben.
The effect of maraviroc on
Vpliv maraviroka na digoksin v
The effect of MicardisPlus may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinek zdravila MicardisPlus se lahko zmanjša, če jemljete NSAR (nesteroidne antirevmatike, npr. acetilsalicilno kislinoali ibuprofen).
The effect of multiple MabThera courses on the development of neutropenia in granulomatosis with polyangiitis and microscopic polyangiitis patients has not been studied in clinical trials.
V kliničnih preskušanjih niso raziskali vpliva več ciklov zdravila MabThera na pojav nevtropenije pri bolnikih z granulomatozo s poliangiitisom ali mikroskopskim poliangiitisom.
The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.
Hidroklorotiazid lahko poveča učinek nedepolarizirajočih relaksantov skeletnih mišic.
The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide;
Hidroklorotiazid lahko potencira delovanje nedepolarizirajočih relaksantov skeletnega mišičja.
The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion or causing total posterior vitreous detachment [PVD]) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA > 1500 microns (see section 5.1).
Učinek okriplazmina (zlasti pri induciranju odprave vitreomakularne adhezije ali povzročitvi popolnega posteriornega odstopa steklovine [PVD – Posterior Vitreous Detachment]) je manjši pri bolnikih z epiretinalno membrano (ERM) ali premerom vitreomakularne adhezije >1500 mikronov (glejte poglavje 5.1).
The effect of OPTISON on pulmonary haemodynamics was studied in a prospective, open-label study of 30 patients scheduled for pulmonary artery catheterisation, including 19 with an elevated baseline pulmonary arterial systolic pressure (PASP) (>35 mmHg; mean 70.1±33.0 mmHg; range 36.0-176.0 mmHg) and 11 with a normal PASP (≤35 mmHg; mean 29.3±4.6 mmHg; range 22.0-35.0 mmHg).
Učinek zdravila OPTISON na pljučno hemodinamiko so preučevali v perspektivni, odprti študiji na 30 bolnikih, naročenih na kateterizacijo pljučne arterije, vključno z 19 bolniki s povišanim sistolnim tlakom v pljučni arteriji (PASP) glede na izhodišče (>35 mmHg; povprečje 70,1 ± 33,0 mmHg; obseg 36,0-176,0 mmHg) in 11 bolniki z normalnim PASP (≤ 35 mmHg; povprečje 29,3 ± 4,6 mmHg; obseg 22,0-35,0 mmHg).
The effect of other H2 receptor antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. omeprazole) that may suppress gastric acidity for several hours on plasma levels of posaconazole has not been studied but a reduction in bioavailability may occur so that co- administration should be avoided if possible.
Učinka drugih antagonistov receptorjev H2 (npr. famotidin, ranitidin) in zaviralcev protonske črpalke (npr. omeprazol), ki lahko zmanjšajo kislost v želodcu za več ur, na plazemske koncentracije posakonazola še niso proučevali, vendar bi lahko prišlo do zmanjšanja biološke uporabnosti, zato se je potrebno sočasni uporabi izogibati, če je le mogoče.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
18-tedenskem preskušanju pri diabetikih tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinek pioglitazona (45 mg monoterapija v primerjavi s placebom) so preučevali v majhnem 18- tedenskem preskušanju pri bolnikih s sladkorno boleznijo tipa 2.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Učinek pioglitazona (45 mg monoterapija v primerjavi s placebom) so preučevali v majhnem 18- tedenskem preskušanju pri diabetikih tipa 2.
The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
Vpliv zdravila Praluent na kardiovaskularno obolevnost in umrljivost še ni ugotovljen.
The effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Učinkovitost presornih aminov se lahko zmanjša, vendar ne za toliko, da bi bilo treba zdravljenje zato ustaviti.
The effect of race on metabolism of pitolisant has not been evaluated.
Vpliv rase na presnovo pitolizanta ni bil ovrednoten.
The effect of race on metabolism of sodium oxybate has not been evaluated.
Vpliva rase na presnovo natrijevega oksibata niso ovrednotili.
The effect of Repatha on cardiovascular morbidity and mortality has not yet been demonstrated.
Učinek zdravila Repatha na srčno-žilno obolevnost in umrljivost še ni bil dokazan.
The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.
Učinek zdravila Repatha na srčno-žilno obolevnost in umrljivost še ni bil ugotovljen.
The effect of Resolor on spontaneous bowel movements (SBM) also proved to be statistically superior to placebo for the portion of patients that had an increase of ≥1 SBM/week over the 12-week treatment period.
Tudi učinki zdravila Resolor na spontano odvajanje blata (SBM – spontaneous bowel movements) so bili statistično boljši kot placebo za delež bolnikov s povečanjem ≥1 SBM/teden v 12-tedenskem obdobju zdravljenja.
The effect of selexipag on progression of PAH was demonstrated in a multi-centre, long-term (maximum duration of exposure approximately 4.2 years), double-blind, placebo-controlled, parallel-group, event-driven Phase 3 study in 1,156 patients with symptomatic (WHO FC I–IV) PAH.
Učinek seleksipaga na napredovanje PAH so dokazali v multicentrični, dolgotrajni (največje trajanje izpostavljenosti približno 4,2 leti), dvojno slepi, s placebom nadzorovani, študiji faze 3 z vzporednimi skupinami, odvisni od dogodkov, s 1.156 bolniki s simptomatsko PAH (FR I–IV po SZO).
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of elvitegravir, cobicistat, or tenofovir alafenamide has not been studied.
Učinka hude jetrne okvare (stopnje C po Child-Pughu) na farmakokinetiko elvitegravirja, kobicistata ali alafenamidtenofovirata niso proučevali.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied.
Učinka hude jetrne okvare (stopnje C po Child-Pughu) na farmakokinetiko alafenamidtenofovirata niso proučevali.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied.
Učinka hude jetrne okvare (stopnje C po Child-Pughu) na farmakokinetične lastnosti alafenamidtenofovirata niso proučevali.
The effect of severe hepatic impairment on the pharmacokinetics of darunavir has not been studied (see sections 4.2, 4.3 and 4.4).
Učinkov hude jetrne okvare na farmakokinetiko darunavirja še niso preučevali (glejte poglavja 4.2, 4.3 in 4.4).
The effect of showering on the absorption of oxybutynin was evaluated in a randomised, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after Kentera application (N=20).
Vpliv prhanja na absorpcijo oksibutinina so ocenili v randomizirani navzkrižni študiji dinamičnega ravnovesja, pod naslednjimi pogoji: brez prhanja ali s prhanjem 1, 2 ali 6 ur po aplikaciji zdravila Kentera (n = 20).
The effect of strong inhibitors of these isozymes on axitinib pharmacokinetics has not been studied.
Vpliva močnih zaviralcev teh izoencimov na farmakokinetiko aksitiniba niso raziskovali.
The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after Kentera application was evaluated in a single-dose randomised crossover study (N=16).
Vpliv kreme za sončenje na absorpcijo oksibutinina, pri nanašanju 30 minut pred aplikacijo zdravila Kentera ali 30 minut po njej, so ocenili v randomizirani navzkrižni študiji z enkratnim odmerkom (n = 16).
The effect of Telmisartan Teva may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinek zdravila Telmisartan Teva se lahko zmanjša, če jemljete NSAID (nesteroidna protivnetna zdravila, npr. acetilsalicilna kilsina, ibuprofen) ali kortikosteroide.
The effect of Telmisartan Teva Pharma may be reduced when you take NSAIDs (non steroidal anti- inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinek zdravila Telmisartan Teva Pharma se lahko zmanjša, če jemljete NSAID (nesteroidna protivnetna zdravila, npr. acetilsalicilna kilsina, ibuprofen) ali kortikosteroide.
The effect of the combination on the patient’s QTc interval should be evaluated with pre- and post-dose ECGs.
Učinek te kombinacije na bolnikov interval QTc je treba pred odmerjanjem in po njem oceniti z EKG.
The effect of the lower dose of ADROVANCE (alendronate 70 mg/vitamin D3 2,800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post- menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Vpliv manjšega odmerka zdravila ADROVANCE (alendronat 70 mg/vitamin D3 2.800 i.e.) na status vitamina D so ugotavljali v 15-tedenski, mednarodni študiji, v katero je bilo vključenih 682 žensk s pomenopavzalno osteoporozo (serumski 25-hidroksivitamin D ob začetku študije: povprečna vrednost 56 nmol/l [22,3 ng/ml]; obseg vrednosti 22,5–225 nmol/l [9–90 ng/ml]).
The effect of the lower dose of FOSAVANCE (alendronate 70 mg/vitamin D3 2,800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Vpliv nižjega odmerka zdravila FOSAVANCE (alendronat 70 mg/vitamin D3 2.800 i.e.) na status vitamina D so ugotavljali v 15-tedenski, mednarodni študiji, v katero je bilo vključenih 682 žensk s pomenopavzalno osteoporozo (serumski 25-hidroksivitamin D ob začetku študije: povprečna vrednost 56 nmol/l [22,3 ng/ml]; obseg vrednosti 22,5–225 nmol/l [9–90 ng/ml]).
The effect of the lower dose of VANTAVO (alendronate 70 mg/vitamin D3 2800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [22.3 ng/ml]; range, 22.5-225 nmol/l [9-90 ng/ml]).
Vpliv nižjega odmerka zdravila VANTAVO (alendronat 70 mg/vitamin D3 2.800 i.e.) na status vitamina D so ugotavljali v 15-tedenski, mednarodni študiji, v katero je bilo vključenih 682 žensk s pomenopavzalno osteoporozo (serumski 25-hidroksivitamin D ob začetku študije: povprečna vrednost 56 nmol/l [22,3 ng/ml]; obseg vrednosti 22,5–225 nmol/l [9–90 ng/ml]).
The effect of the medicine was compared with placebo (a dummy treatment) and the main measure of effectiveness was the proportion of patients who responded to treatment for at least 18 weeks, as shown by a 50% reduction (‘partial response’) or complete disappearance (‘complete response’) of tumours and symptoms of the disease.
Učinek zdravila so primerjali s placebom (zdravilom brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bil delež bolnikov, ki so se odzivali na zdravljenje vsaj 18 tednov, kar je pomenilo, da so se tumorji in simptomi bolezni zmanjšali za 50 % („delni odziv“) ali pa so popolnoma izginili („popolni odziv“).
The effect of the vaccine in the per-protocol analysis was a 9 % reduction (95 % CI: 3, 15) in recurrent AOM (defined as 3 episodes in six months or 4 episodes in one year) or a 23 % (95 % CI: 7,36) reduction for recurrent AOM (5 episodes in six months or 6 episodes in one year).
Pri otrocih, ki so opravili vsa cepljenja skladno s protokolom cepljenja, se je ponovno akutno vnetje srednjega ušesa (ki je bilo definirano kot 3 izbruhi v pol leta ali 4 izbruhi v enem letu) zmanjšalo za 9 % (95-odstotni interval zaupanja: 3, 15), ponovno akutno vnetje srednjega ušesa (definirano kot 5 izbruhov v pol leta ali 6 izbruhov v enem letu) pa za 23 % (95-odstotni interval zaupanja: 7, 36).
The effect of this medicine on human fertility has not been investigated.
Učinka tega zdravila na plodnost pri ljudeh niso proučevali.
The effect of those anticonvulsant agents on busulfan pharmacokinetics was investigated in a phase II study (see section 4.5).
Učinek teh protikonvulzivnih učinkovin na farmakokinetiko busulfana so raziskovali v študiji II. faze (glejte poglavje 4.5).
The effect of Tolucombi may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinek zdravila Tolucombi se lahko zmanjša, če jemljete NSAR (nesteroidne antirevmatike, npr. acetilsalicilno kislino ali ibuprofen).
The effect of Tolura may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids.
Učinek zdravila Tolura se lahkozmanjša, če jemljete nesteroidna protivnetna zdravila (npr. aspirin ali ibuprofen) ali kortikosteroide.
The effect of treatment initiation with a dosing regimen of Invirase/ritonavir 500 /100 mg twice daily in combination with 2 NRTIs for the first 7 days of treatment followed by Invirase/ritonavir 1000 / 100 mg twice daily in combination with 2 NRTIs in the subsequent 7 days on QTc interval, PK, and viral load was evaluated in an open-label 2-week observational study in 23 HIV-1 infected, treatment- naïve patients initiating Invirase/ritonavir therapy.
V odprti 2-tedenski opazovalni študiji so pri 23 bolnikih, okuženih s HIV-1, ki še niso bili zdravljeni in so začeli z zdravljenjem z zdravilom Invirase/ritonavirjem, ocenjevali učinek začetnega zdravljenja na interval QTc, PK in virusno breme, z režimom odmerjanja zdravila Invirase/ritonavirja 500/100 mg dvakrat na dan v kombinaciji z dvema NRTI – nukleozidnima zaviralcema reverzne transkriptaze prvih 7 dni zdravljenja, ki mu je v naslednjih 7 dneh sledilo zdravljenje z zdravilom Invirase/ritonavirjem 1000/100 mg dvakrat na dan v kombinaciji z dvema NRTI.